These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 33179573)

  • 21. Critical appraisal of the application of propensity score methods in the urology literature.
    Nayan M; Hamilton RJ; Juurlink DN; Finelli A; Kulkarni GS; Austin PC
    BJU Int; 2017 Dec; 120(6):873-880. PubMed ID: 28608364
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Using Propensity Scores for Causal Inference: Pitfalls and Tips.
    Shiba K; Kawahara T
    J Epidemiol; 2021 Aug; 31(8):457-463. PubMed ID: 34121051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis.
    Lefort M; Sharmin S; Andersen JB; Vukusic S; Casey R; Debouverie M; Edan G; Ciron J; Ruet A; De Sèze J; Maillart E; Zephir H; Labauge P; Defer G; Lebrun-Frenay C; Moreau T; Berger E; Clavelou P; Pelletier J; Stankoff B; Gout O; Thouvenot E; Heinzlef O; Al-Khedr A; Bourre B; Casez O; Cabre P; Montcuquet A; Wahab A; Camdessanché JP; Maurousset A; Ben Nasr H; Hankiewicz K; Pottier C; Maubeuge N; Dimitri-Boulos D; Nifle C; Laplaud DA; Horakova D; Havrdova EK; Alroughani R; Izquierdo G; Eichau S; Ozakbas S; Patti F; Onofrj M; Lugaresi A; Terzi M; Grammond P; Grand'Maison F; Yamout B; Prat A; Girard M; Duquette P; Boz C; Trojano M; McCombe P; Slee M; Lechner-Scott J; Turkoglu R; Sola P; Ferraro D; Granella F; Shaygannejad V; Prevost J; Maimone D; Skibina O; Buzzard K; Van der Walt A; Karabudak R; Van Wijmeersch B; Csepany T; Spitaleri D; Vucic S; Koch-Henriksen N; Sellebjerg F; Soerensen PS; Hilt Christensen CC; Rasmussen PV; Jensen MB; Frederiksen JL; Bramow S; Mathiesen HK; Schreiber KI; Butzkueven H; Magyari M; Kalincik T; Leray E
    BMC Med Res Methodol; 2022 May; 22(1):155. PubMed ID: 35637426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Covariate adjustment in subgroup analyses of randomized clinical trials: A propensity score approach.
    Yang S; Li F; Thomas LE; Li F
    Clin Trials; 2021 Oct; 18(5):570-581. PubMed ID: 34269087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A review of the performance of different methods for propensity score matched subgroup analyses and a summary of their application in peer-reviewed research studies.
    Wang SV; He M; Jin Y; Wyss R; Shin H; Ma Y; Keeton S; Fireman B; Karami S; Major JM; Schneeweiss S; Gagne JJ
    Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1507-1512. PubMed ID: 28984001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Which Propensity Score Method Best Reduces Confounder Imbalance? An Example From a Retrospective Evaluation of a Childhood Obesity Intervention.
    Schroeder K; Jia H; Smaldone A
    Nurs Res; 2016; 65(6):465-474. PubMed ID: 27801717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterizing Imbalance in the Tails of the Propensity Score Distribution.
    DiPrete BL; Girman CJ; Mavros P; Breskin A; Brookhart MA
    Am J Epidemiol; 2024 Feb; 193(2):389-403. PubMed ID: 37830395
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of approaches for stratifying on the propensity score to reduce bias.
    Linden A
    J Eval Clin Pract; 2017 Aug; 23(4):690-696. PubMed ID: 28074629
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
    Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
    Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Theory and practice of propensity score analysis.
    Hashimoto Y; Yasunaga H
    Ann Clin Epidemiol; 2022; 4(4):101-109. PubMed ID: 38505253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Overview on the generalized propensity scoring estimator for continuous treatment].
    Zhang Y; Gao Q; Wang T
    Zhonghua Liu Xing Bing Xue Za Zhi; 2022 Apr; 43(4):572-577. PubMed ID: 35443315
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003.
    Austin PC
    Stat Med; 2008 May; 27(12):2037-49. PubMed ID: 18038446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Propensity score matching in otolaryngologic literature: A systematic review and critical appraisal.
    Prasad A; Shin M; Carey RM; Chorath K; Parhar H; Appel S; Moreira A; Rajasekaran K
    PLoS One; 2020; 15(12):e0244423. PubMed ID: 33382777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.
    He A; Merkel B; Brown JWL; Zhovits Ryerson L; Kister I; Malpas CB; Sharmin S; Horakova D; Kubala Havrdova E; Spelman T; Izquierdo G; Eichau S; Trojano M; Lugaresi A; Hupperts R; Sola P; Ferraro D; Lycke J; Grand'Maison F; Prat A; Girard M; Duquette P; Larochelle C; Svenningsson A; Petersen T; Grammond P; Granella F; Van Pesch V; Bergamaschi R; McGuigan C; Coles A; Hillert J; Piehl F; Butzkueven H; Kalincik T;
    Lancet Neurol; 2020 Apr; 19(4):307-316. PubMed ID: 32199096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methods for estimating subgroup effects in cost-effectiveness analyses that use observational data.
    Kreif N; Grieve R; Radice R; Sadique Z; Ramsahai R; Sekhon JS
    Med Decis Making; 2012; 32(6):750-63. PubMed ID: 22691446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of propensity score and disease risk score for multiple treatments with time-to-event outcome: a simulation study.
    Zhang D; Kim J
    J Biopharm Stat; 2019; 29(6):1103-1115. PubMed ID: 30831052
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variable selection for propensity score models when estimating treatment effects on multiple outcomes: a simulation study.
    Wyss R; Girman CJ; LoCasale RJ; Brookhart AM; Stürmer T
    Pharmacoepidemiol Drug Saf; 2013 Jan; 22(1):77-85. PubMed ID: 23070806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Matching on the disease risk score in comparative effectiveness research of new treatments.
    Wyss R; Ellis AR; Brookhart MA; Jonsson Funk M; Girman CJ; Simpson RJ; Stürmer T
    Pharmacoepidemiol Drug Saf; 2015 Sep; 24(9):951-61. PubMed ID: 26112690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The z-difference can be used to measure covariate balance in matched propensity score analyses.
    Kuss O
    J Clin Epidemiol; 2013 Nov; 66(11):1302-7. PubMed ID: 23972521
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primer on statistical interpretation or methods report card on propensity-score matching in the cardiology literature from 2004 to 2006: a systematic review.
    Austin PC
    Circ Cardiovasc Qual Outcomes; 2008 Sep; 1(1):62-7. PubMed ID: 20031790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.